Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Deutsche Bank downgrades Fever-Tree, says Molson Coors deal 'lacks near-term fizz'

(Sharecast News) - Deutsche Bank downgraded Fever-Tree Drinks on Monday to 'hold' from 'buy' and slashed the price target to 800p from 1,325p as it said the deal with Molson Coors "lacks near-term fizz". Fever-Tree announced last month that the Coors Light maker would be buying an 8.5% stake in the posh tonic maker for £71m in cash, with the proceeds set to be returned to shareholders via a share buyback programme.

The company said it had entered into a long-term strategic partnership with Molson Coors for the exclusive sales, distribution and production of the Fever-Tree brand in the US.

Deutsche bank said that initially, it thought the deal with Molson Coors represented a positive move for the Fever-Tree brand in the US and the overall investment case for the equity.

"Having modelled out the details of the partnership, we still think it is a positive strategic step for the US growth opportunity but the negative impact on the near term financials mean any potential meaningful upside is several years away, in our view," it said.

DB said the partnership arrangement fundamentally changes the group margin recovery opportunity, which its previous 'buy' case was predicated on.

"Previously, we modelled group adjusted EBITDA margins recovering to mid-twenties by FY28E, which underpinned a more than 40% adjusted EPS compound annual growth rate across FY24-28E," it said.

"On our updated forecasts, the new structure limits margin progression to 17% by FY28E, and indicates 17.5% adjusted EPS CAGR over the same time frame."

At 0920 GMT, the shares were down 2.2% at 702.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.